A device for delivery of particles into biological tissue includes at least one conduit and a propellant source fluidically coupled to the conduit and configured to deliver a propellant into the conduit. A particle source is configured to release elongated particles into the conduit, the elongated particles having a width, w, a length, l>w. The propellant source and the conduit are configured to propel the elongated particles in a collimated particle stream toward the biological tissue. An alignment mechanism is configured to align a longitudinal axis of the elongated particles to be substantially parallel to a direction of the particle stream in an alignment region of the conduit. The aligned elongated particles are ejected from the conduit and impact the biological tissue.

An electric device for performing a skin allergy test. The device has a main body having a metallic tip installed on the top thereof, and means of generation, transmission and control of an electric pulse contained inside the main body and electrically connected to the tip. The device includes a hollow outer nozzle having a cylindrical shape is located at the top of the main body that contains the tip inside so that it is not visible from outside. The device further includes means with a related tank releasing ink so that when the nozzle and the tip are placed in contact with a patient's skin then a series of ink marks are printed in sequence on the skin. Furthermore, an electric pulse is emitted on command, for each of the ink marks so that the pulse emitted from the tip generates a respective small surface hole on the skin.

A treatment system can include a channel generation system configured to expose an infected region of a target tissue with a laser beam traveling along an optical axis and focused at a focal volume located in or adjacent to the target tissue. The laser beam can have a wavelength ranging from about 100 nm to about 400 nm. The laser beam can be configured to generate at least a first channel in the infected region. The treatment system can also include a detection system configured to detect a first radiation generated by one or more of (i) the target tissue, (ii) a fungi coupled to the infected region in the target tissue, and (iii) an adjacent tissue located proximal to the target tissue as a result of interaction with the laser beam. The treatment system can also include a delivery system configured to deposit an active treatment agent in the at least first channel.

A device and method for delivery of a bioactive agent across a dermal barrier of a subject. The device including a microneedle with a channel and a plurality of nanostructures and microstructures located on the microneedle. The nanostructures and microstructures are arranged in a fractal-like pattern. A reservoir is in fluid communication with the channel and contains a composition having a viscosity of greater than about 5 centipoise and comprising a bioactive agent. The method includes penetrating a stratum corneum of the subject with the microneedle and transporting a composition through the microneedle at a rate of greater than about 0.4 mg/hr/cm2 based upon the surface area of the microneedle.

A system and method are provided for performing predictive permeation on the skin of a patient, particularly where the skin has no corneum. For this purpose, a device is provided which has an elongated probe, with an electrode array that extends along an active segment of the probe. Also, a voltage source is connected to the electrode array to generate an electric field. Operationally, an electro-conductive emulsion is applied onto the skin of the patient where the predictive permeation procedure is to be performed and the probe is positioned to contact the skin to be treated. The emulsion then interacts with the electric field that is generated by the electrode array to increase the permeability of the skin. Particles from a blood sample of the patient are included in the emulsion, and are introduced into the skin during the predictive permeation procedure to increase skin density.

Described herein are drug and other active agent transdermal delivery systems and devices to deliver active agents to skin or mucosa of a subject, and methods of delivering such active agents. In particular, systems, methods, and devices are described that control the concentration and timing of active agent delivery. Such systems or devices may include a transdermal membrane and a temperature control element for heating and/or cooling a portion of the transdermal delivery system to provide pulsatile active agent delivery through the transdermal membrane.

An iontophoresis system includes a preloaded reservoir containing one or more doses of a therapeutic agent. As a result, the therapeutic agent does not have to be loaded into the reservoir prior to use. In such a system, the preloaded reservoir is generally disposable. Various components of the iontophoresis system can be combined with the reservoir in a disposable cartridge that is selectively connectable to other, reusable components of the iontophoresis system. In addition, the entire iontophoresis system can be formed from one or more disposable, one-time-use modules.

A method and apparatus for promoting the delivery of a molecule across a cell membrane comprises delivering a molecule to a delivery site of a region of tissue surrounding the cell membrane. A suction component applies a suction through a suction tip that surrounds the surface of the delivery site creating a seal to promote delivery of the molecule across the cell membrane. The application of the suction is controlled to create a predetermined negative pressure for a predetermined period of time before releasing the negative pressure. Suction is used to enhance permeabilization and transfection of cells. The technique can be used to enhance the uptake and subsequent transfection and expression of plasmid DNA vaccines, mRNA vaccines and other nucleic acid molecules, that are introduced subcutaneously. It can be used in combination with coated microneedles.

An adjustable clamping-type ultrasonic medicine-applying massage device, including a left clamping arm, a right clamping arm, an intermediate hinge adjustment and ultrasonic medicine-applying massage heads; an end of the left clamping arm is in an articulated connection with an end of the right clamping arm through the intermediate hinge adjustment mechanism; an operating space is formed in an area where the left clamping arm and the right clamping arm face to each other; another end of the left clamping arm and another end of the right clamping arm are each provided with a ultrasonic medicine-applying massage head; the ultrasonic medicine-applying massage head of the left clamping arm and the ultrasonic medicine-applying massage head of the right clamping arm face towards each other.

A system includes a nose-to-brain medication delivery device including a medication dispersion device and a magnetic field generator. The generator, when in use, generates a magnetic field of sufficient strength and direction to reposition an ionized and/or magnetized medication to a selected drug delivery site on the brain following initial delivery of the medication from the medication delivery device to the brain cavity via the nose while bypassing the blood-brain barrier.